Sands Capital Life Sciences Pulse Fund II, L.P. — Form SCHEDULE 13D/A
Filed July 7, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Sands Capital Life Sciences Pulse Fund II, L.P. filed a Schedule 13D/A amendment on July 7, 2026, updating its beneficial ownership statement in Alamar Biosciences, Inc. (a Delaware-incorporated laboratory analytical instruments company). The filing document itself does not display in this submission, so specific share counts, percentages, or the nature of the ownership change cannot be determined from the text provided.
Why this rating
Schedule 13D/A amendments are routine disclosure updates. No material change details, dollar amounts, or strategic implications are visible in the filing header. Routine compliance filing.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.